Immucor Inc.(BLUD) recently reported a company record for net income in a quarter and completed an acquisition. Earnings are showing solid growth for next year and are traded at a fair value.

Company Description

Immucor is an international in vitro diagnostic company dedicated to automating manual processes in the hospital/donor laboratory. They develop, manufacture, and sell products used by hospital blood banks, clinical laboratories, and large blood-donor centers to test, detect, and identify certain properties of human blood prior to patient transfusion.

Immucor’s instruments utilize patented solid phase technology reagents to perform ABO grouping tests, RH typing, antibody screening, and platelet cross-matching.

Record First Quarter Results

On Oct 1 Immucor announced one of the best quarters in company history that included revenues of $73.2 million, a 15% year-over-year increase. About 75% of the revenue growth came from the U.S.

Net income for the quarter was $20 million, the highest in company history. The figure translates to earnings of 28 cents per share. Wall Street was expecting 23 cents per share, making it the third consecutive earnings surprise.

Dr. De Chirico, President and CEO said, “All-time highs were achieved in revenues, and net income for the quarter as our strategies to grow our business and the execution of our plan once again generated outstanding results.”

Growth With Reasonable Valuations

The current consensus for next year, fiscal 2010, is $1.16. The forecast represents a year-over-year increase of 19%. The current long-term growth rate is 20%, which brings the relatively high P/E ratio of 23.4 to a PEG ratio of 1.3.

Acquisition Complete

Immucor completed a previously announced deal to acquire BioArray Sollutions, a molecular diagnostic company specializing in blood transfusions. The cash only deal was valued at $108.2 million.

The Chart

Shares of BLUD have been bouncing off of support at $22 per share. The level has been tested several times and is holding well. Take a look at the chart below.

Content Courtesy: Zacks Investment Research

#1 Ranked Stocks Highlight Archive
To truly take advantage of the Zacks Rank, you need to first understand how it works. That is why we created the free special report: Zacks Rank Guide: Harnessing the Power of Earnings Estimate Revisions.

Similar Posts: BLUD | Immucor Inc. | VitalStocks | Diagnostic Substances | Healthcare

RSS feeds: BLUD | Immucor Inc. | VitalStocks | Diagnostic Substances | Healthcare |

Other Posts by Shawn | RSS Feed for this author